Daniele Guyot-Caparros
Director at DBVT
Board
About Daniele Guyot-Caparros
Independent director with deep finance and operations expertise across pharma/biotech. Age 66 (as of April 15, 2025), appointed to DBV’s Board in October 2022; current term expires at the 2027 AGM cycle. Education: ICN (Institut Commercial de Nancy), specialization in finance/accounting; higher accounting degree; independent director certificate (IFA–Sciences-Po). Classified independent under Nasdaq and French law.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| PwC | Auditor; corporate finance focus in chemicals/pharma | Early career (not dated) | Built corporate finance skill set in sector verticals |
| Rhône-Poulenc-Rorer (later Aventis → Sanofi) | CFO R&D worldwide; CFO Europe; Head of Pharmaceutical Operations Plan | Joined 1992 (subsequent senior international responsibilities) | Business development and product portfolio optimization |
| Deloitte Conseil (France) | Senior Advisor | From 2008 | Numerous mandates in pharma/biotech/medtech; transformation, governance, M&A focus |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Valneva SE (Nasdaq/Euronext) | Director; Audit Committee Chair | Jun 2024–Jun 2027; Chair since Oct 2024 | Audit leadership; financial oversight |
| Diaxonhit (Eurobio Scientific) | Supervisory Board member; Audit Committee member | 2015–2017 | Governance and audit oversight |
| Supersonic Imagine | Audit Committee Chair | Until 2019 (company acquired by Hologic) | Chaired audit until takeover |
| ONXEO | Director; Audit Committee Chair; Board Chair | Director: 2013–Jun 2023; Chair: May 2019–Jul 2021 | Board and audit leadership at clinical-stage biotech |
Board Governance
- Committee assignments: Audit Committee member; Compensation Committee member (not chair). Audit Committee chaired by Timothy E. Morris; Compensation Committee chaired by Julie O’Neill.
- Independence: Board determined all directors except CEO Daniel Tassé, Michael J. Goller (Baker Bros.), and Maïlys Ferrère (Bpifrance) are independent; Guyot-Caparros is independent per Nasdaq and French requirements.
- Attendance: In 2024, each director attended at least 94% of Board meetings and 100% of the committees they served on; all directors attended the May 16, 2024 AGM.
- Executive sessions: Independent directors meet in regular executive sessions throughout the year.
Committee Membership Summary
| Committee | Member | Chair |
|---|---|---|
| Audit | Yes | No (Chair: Morris) |
| Compensation | Yes | No (Chair: O’Neill) |
| Nominating & Governance | No | Chair: Goller |
Fixed Compensation
| Year | Component | Amount | Notes |
|---|---|---|---|
| 2024 | Total director fees (cash) | $115,478 | Fees denominated/paid in EUR; converted at €1.00=$1.0498; no equity to Guyot-Caparros in 2024 |
| 2025 policy (illustrative structure) | Base director retainer (EUR) | €100,000 | Excludes Chairman and CEO; attendance-based payout (≥90% for full amount) |
| 2025 policy (committee membership) | Per committee membership (EUR) | €5,000 | Applies to Audit/Comp/NomGov members; pro rata for <90% attendance |
| 2025 policy (committee chairs) | Audit Chair; Comp Chair; NomGov Chair (EUR) | €20,000; €10,000; €10,000 | Incremental fees for chair roles |
| 2025 budget | Aggregate director compensation budget (EUR) | €900,000 | Increased from €800,000, subject to AGM approval; approved June 11, 2025 |
No meeting fees disclosed beyond attendance-conditioned payout; reasonable expenses reimbursable per policy.
Performance Compensation
- No equity (RSUs/options) or performance-linked director awards reported for Guyot-Caparros in 2024; Company policy allows potential issuance of director warrants at fair market value, but none are listed for Guyot-Caparros.
Other Directorships & Interlocks
| Company | Overlap/Interlock Considerations |
|---|---|
| Valneva SE | Another French/EU biotech; audit chair duties could enhance cross-board financial oversight, but raises time/attention considerations typical for multi-board directors |
| ONXEO, Supersonic Imagine, Diaxonhit/Eurobio Scientific | Prior governance roles across EU medtech/biotech; no DBV-disclosed related-party transactions involving Guyot-Caparros |
Expertise & Qualifications
- Financial leadership across pharma (global R&D CFO, Europe CFO), operations planning, and portfolio optimization.
- M&A, transformation, and governance advisory experience at Deloitte Conseil.
- Audit leadership across multiple listed biotechs; independent director credential (IFA–Sciences-Po).
Equity Ownership
| Holder | Beneficial Ownership (Shares) | % of Outstanding | Notes |
|---|---|---|---|
| Daniele Guyot-Caparros | — | — | No beneficial ownership listed; not among non-employee directors with warrants |
- Hedging prohibited under DBV’s Securities Trading Policy; no pledging policy disclosure in proxy.
Employment & Contracts (Director Mandate)
| Role | Term End | Employment Contract | Service Agreement | Revocation/Termination |
|---|---|---|---|---|
| Director | AGM to approve FY 2027 accounts | No | No | Per French law/case law; standard director mandate terms |
Governance Assessment
-
Strengths
- Independent status with deep audit/finance expertise; active service on DBV’s Audit and Compensation Committees.
- High engagement: ≥94% Board attendance and 100% committee attendance in 2024.
- Shareholder support: 2025 AGM approved all resolutions, including director compensation policy and increased director budget.
- Oversight of related-party transactions resides with Audit Committee; formal policy and procedures in place.
-
Watch items
- Ownership alignment: No reported share or warrant holdings; cash-heavy director pay profile (common in EU issuers) may signal lower “skin-in-the-game.”
- Multi-board commitments (Valneva SE audit chair and DBV committees) require continued strong attendance to avoid dilution of focus; policy includes attendance thresholds for full fee payout.
- Capital structure complexity (PIPE with warrants, major holders Baker Bros/Bpifrance) elevates oversight demands; Audit Committee monitors related-party transactions.
-
Red flags observed: None disclosed specific to Guyot-Caparros (no Section 16 issues; no related-party transactions; no hedging/pledging exceptions reported).